Let us settle the controversy—gelfoam is a safe intravascular embolic agent
British Journal of Radiology · 07.05.2024 · 97 (1157) · 933-937
DOI: 10.1093/bjr/tqae047 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Radiology, online erschienen am 24.02.2024. Verfasst von Warren Clements und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Alfred Health, Melbourne 3004, Australia. Hauptthemen laut MEDLINE: Gelatin Sponge, Absorbable, Embolization, Therapeutic, Hemorrhage. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
A 2021 safety alert restricted endovascular gelfoam use in Australia and resulted in an embargo on gelfoam sales to Interventional Radiology departments. This study aimed to show that gelfoam is safe in a population of trauma patients with pelvic injury, and discuss the basis of the recent controversies.
Methods
Retrospective cohort study was conducted between 1 January 2010 and 21 May 2021 for the patients who underwent gelfoam embolization for pelvic arterial haemorrhage. Primary outcome was the rate of adverse events related to intravascular gelfoam administration.
Results
Inclusion criteria met in 50 patients, comprising 58% males median age 59.9 years, and median injury severity score 31. There were 0 complications related to gelfoam use and 100% technical success. Thirty-five patients (70%) received a non-targeted embolization approach. All-cause mortality was observed in 5 patients (10%), unrelated to gelfoam.
Conclusions
Gelfoam is a safe and effective embolic agent in pelvic trauma. Patients are in urgent need of universal on-label registration of endovascular gelfoam products, as it is life-saving in major haemorrhage after trauma. Advances in knowledge Endovascular gelfoam is mandatory for a high-quality trauma service, and this study shows that it is safe to use intentionally in the endovascular space. Companies should work with interventional radiologists, sharing and collaborating to ensure positive outcomes for patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Alfred Health, Melbourne 3004, Australia.
- Department of Surgery, Central Clinical School, Monash University, Melbourne 3004, Australia.
- National Trauma Research Institute, Central Clinical School, Monash University, Melbourne 3004, Australia.
- Department of Trauma, Alfred Health, Melbourne 3004, Australia.
ORCID-Profile: Warren Clements
Zitieren
APA
Clements, W., Lukies, M., Zia, A., Fitzgerald, M., & Kavnoudias, H. (2024). Let us settle the controversy—gelfoam is a safe intravascular embolic agent. British Journal of Radiology, 97(1157), 933-937. https://doi.org/10.1093/bjr/tqae047
Vancouver
Clements W, Lukies M, Zia A, Fitzgerald M, Kavnoudias H. Let us settle the controversy—gelfoam is a safe intravascular embolic agent. British Journal of Radiology. 2024;97(1157):933-937. doi:10.1093/bjr/tqae047
BibTeX
@article{Clements2024,
author = {Clements, Warren and Lukies, Matthew and Zia, Adil and Fitzgerald, Mark and Kavnoudias, Helen},
title = {Let us settle the controversy—gelfoam is a safe intravascular embolic agent},
journal = {British Journal of Radiology},
year = {2024},
volume = {97},
number = {1157},
pages = {933--937},
doi = {10.1093/bjr/tqae047}
}
EUVIMED